🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is it time to screen for multiple myeloma? | Blood | American Society of Hematology #mmsm ashpublications.org/blood/article/…

More than half of patients newly diagnosed with lymphoma or myeloma experience significant anxiety or depression - we should expect therefore that the majority of these patients will need treatment. #mmsm ashpublications.org/bloodadvances/…

Panelists discuss how emerging therapies like bispecific antibodies, CAR T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma. #mmsm | Al Garfall Omar Nadeem Surbhi Sidana, MD cancernetwork.com/view/brief-ove…

Explore this gift article from The New York Times. You can read it for free without a subscription. nytimes.com/2025/02/13/opi…

Urge Congress to Support NIH and Protect Medical Research votervoice.net/Shares/BAAAAAI…

This is exactly right. Gutting the NIH will lead to a rapid labor shortage and all these jobs going overseas

It's time for the #FiveUnder5! Check out the top 5️⃣ #oncology clips of the week: onclive.com/view/five-unde… William K. Oh MD Smilow Cancer Hospital Al Garfall Penn Medicine - Abramson Cancer Center Axel S. Merseburger Shilpa Gupta @CleclinicMD Vanderbilt Health #pcsm #mmsm #lymsm #oncology #medtwitter

Modakafusp alfa delivers interferon alfa signaling to CD38+ myeloma, and has a 43% ORR in R/R MM at the recommended phase 2 doses, with primarily hematologic toxicities ashpublications.org/blood/article/… #mmsm Jonathan Kaufman, MD Shebli Atrash

Novel interferon-based antimyeloma activity ashpublications.org/blood/article/… #mmsm #bmtsm

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy ashpublications.org/blood/article-…

Alfred L. Garfall, MD, (Al Garfall) emphasizes the critical importance of the National Institutes of Health funding for biomedical research. Penn Medicine Penn Medicine - Abramson Cancer Center hubs.li/Q039lvDs0

NIH scientists have a cancer breakthrough. Layoffs are delaying it. wapo.st/42yttHQ

Hence, limited duration treatment needs to be evaluated for these drugs in #mmsm Al Garfall is leading LimiTEC study which studies limited duration bispecific. Also open at University of Iowa Chris Strouse and Columbia Raj Chakraborty

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma @BloodJournal #mmsm ✅ modakafusp: immunocytokine directing interferon-α to CD38-positive cells ✅ ~1/2 with prior BCMA ttt ✅median FU: 7.6 mo ✅ORR: 41% in

Very nice study by Susan Bal & Luciano J Costa demonstrating marked reduction in MRD burden after auto SCT in patients receiving quad induction for myeloma #mmsm rdcu.be/ejHBb

In a trial like this, really important to see the pfs not just mrd. We learned from the forte study that while delaying transplant had similar depth of response at an early time point, the pfs was clearly better for the transplant arm.